Puma at Rock Bottom, Novo Nordisk Riding the Weight-Loss Boom and Volatus Aerospace in Rebound Mode: Who Is the High-Flyer?

Puma: A Tough Battle for Margins

Sportswear manufacturer Puma faces the challenge of sustainably defending its profitability in the highly competitive consumer goods market while simultaneously setting new fashion trends that appeal to customers and encourage them to buy its products. However, margin pressure and subdued consumer sentiment in key core markets are noticeably weighing on its operating performance. Nevertheless, management is working hard to streamline internal processes and boost brand appeal through targeted marketing campaigns.

Puma does not have it easy, as the sporting goods manufacturer must hold its own against major competitors like Nike and Adidas. It is managing to do so only to a limited extent right now, as reflected in a subdued EBIT margin.

In addition, recent analyst revisions and management personnel changes are weighing on market sentiment. Bank of America (BofA) has lowered its price target for Puma stock from EUR 26 to 21 and confirmed its "Underperform" rating, while RBC reduced its price target from EUR 25 to 23.

This more skeptical sentiment is accompanied by an upcoming management shake-up at Puma. Chief Sales Officer Matthias Bäumer is leaving the company at the end of September but will remain associated with Puma as a consultant; CEO Arthur Höld will initially take over sales on an interim basis. These restructuring measures underscore the pressure on the sporting goods manufacturer to boost operational efficiency and make up for lost ground in a challenging industry environment. Only time will tell whether this will succeed.

From a technical analysis perspective, things look rather bleak. After rising in April and May to a high of just over EUR 30, the share is now trading below EUR 22. Some might say these are attractive entry prices. That is certainly possible, but the stock has likely fallen this far for a reason, and some analysts have lowered their price targets. Caution, and even a bit of skepticism, is therefore warranted. Only the RSI indicates an oversold condition, which could lead to a technical rebound. However, it is unclear how far this rebound might go.

We now turn to the European healthcare sector, where Novo Nordisk is trying to profitably capture a massive future market.

Novo Nordisk: The Obesity Boom Meets Competitive Pressure

The Danish pharmaceutical company continues to make headlines mainly for its highly sought-after therapies for obesity and diabetes, but it also faces growing pressure from US competitors. The latest study results and strategic realignments underscore management's drive to broaden its research pipeline. Nevertheless, the stock has lost significant ground again in recent weeks as investors fear intensifying margin pressure.

Operationally, however, Novo is aggressively advancing its pipeline to broaden its presence in the global obesity market. For example, the company recently secured additional innovation capacity beyond pure GLP-1 therapies by acquiring three early-stage development programs from the US biotech company Kallyope, including the preclinical drug candidate K-554, and through a collaboration with Orbis Medicines worth up to USD 1.4 billion.

These steps are accompanied by technological collaborations, such as with Anthropic on using AI in drug discovery, as well as a positive EU recommendation for the haemophilia A drug Frehemgo. The market launch is expected as early as the fourth quarter of 2026 in select countries, followed by an EU-wide launch in early 2027.

The stock currently offers a very attractive valuation for long-term investors. The solid dividend policy and the company's leading market position in the promising weight-loss market are positive factors. The 2027 P/E ratio of 13 is also in an attractive range—especially for a growth stock.

The stock has already rebounded from its spring lows around EUR 30 and is currently trading comfortably above that level at EUR 37.50. If it can break through the resistance zone of EUR 42–43, the stock could have the potential to rise to the EUR 50–55 range in the future.

Moving from sports and pharmaceuticals, we now turn to unmanned aerial systems and defence technology. This sector is expected to boom as demand grows amid ongoing geopolitical conflicts. However, civilian applications are also likely to gain importance.

Volatus Aerospace: An Upturn in the Future Market of Drone Technology

In September 2026, Volatus Aerospace achieved significant operational milestones and distinguished itself with major announcements in the defence sector. First, as part of a competitive evaluation process, the company was selected as a qualified supplier for the Canadian government's Defence Drone Initiative (DDI) Marketplace and, shortly thereafter, successfully qualified in all five work streams (including unmanned and autonomous systems, communications and data systems, engineering and integration services, testing and training, and innovation and experimentation).

This qualification puts Volatus in a strong position to bid on future procurement projects for the Canadian Armed Forces and the Coast Guard.

Shortly after this "full qualification," more good news followed: the Canadian government awarded Volatus a 5-year contract for Tactical Intelligence, Surveillance, and Reconnaissance Unmanned Aerial Systems (Tactical ISR UAS) for the Canadian Armed Forces. The first call-off covers 100 systems under a procurement framework with a total value of up to CAD 25 million. In addition, the agreement includes options for the Canadian government to purchase up to 4,900 additional systems.

Delivery of the first batch is scheduled to begin as early as the fourth quarter of 2026. Supported by the Innovation and Manufacturing Centre in Mirabel, Quebec, and the Operations Control Centre in Vaughan, Ontario, the management team led by CEO Glen Lynch is reinforcing its commitment to significantly strengthening the country's defence capabilities.

Given this positive news, it's no surprise that Volatus Aerospace recently broke out of its established wedge pattern on high volume, sending a strong technical signal. After the share price recently climbed from just under CAD 0.50 to CAD 0.67, a healthy and necessary consolidation phase followed, amid relatively modest trading volume. The stock is currently trading at around CAD 0.60, holding above the support zone between CAD 0.54 and CAD 0.59.

If the price falls back into this range, it could offer a compelling entry point for investors, though a direct rally higher is also possible at any time. Sustained momentum will develop, especially if the CAD 0.70 mark breaks, as this would clear the path toward the recent high of CAD 0.80 to 0.90.

With government contracts under its belt and a strong foothold in the Canadian defence ecosystem, management is demonstrating its strength.

Puma remains a classic turnaround candidate in the consumer sector, whose success depends largely on a noticeable recovery in global demand. Novo Nordisk remains the industry leader and must overcome short-term regulatory hurdles in the US, but it is still exceptionally well-positioned for the long term. Volatus Aerospace combines technological innovation with new government contracts and offers risk-tolerant investors an exciting profile in the future market of unmanned drone systems.